Loading provider…
Loading provider…
Hematology & Oncology Physician in Orlando, FL
NPI: 1255315933Primary Practice Location
ORLANDO HEALTH
92 W Miller St, Orlando, FL
Primary Employer
Orlando Health Medical Group Inc
orlandohealth.com
HQ Phone
Get MD Jose's Phone Numberphone_androidMobile
Get MD Jose's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2001 - 2027
TX State Medical License
1999 - 2005

American Board of Internal Medicine
Hematology
University of Texas Health Science Center at Houston
Fellowship • Hematology and Medical Oncology
1998 - 2001
Washington University/B-JH/SLCH Consortium
Residency • Internal Medicine
1995 - 1998
University of Puerto Rico, Medical Sciences Campus
md.rcm.upr.edu
Medical School
Until 1995
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 149 | 209 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 118 | 194 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 34 | 94 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 20 | 83 |
Inherited factor II deficiency with paradoxical hypercoagulability: a case report.
Authors: Mario Madruga, Ariel Perez Perez, Stephen Carlan, Kwabena Ayesu
Journal: Blood Coagul Fibrinolysis
Authors: Mario Madruga, Nawid Sarwari, Jacqueline Kropf, Sammy Moussly
Journal: J Hematol
Publication Date: 2019-09-30
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Biospecimen Collection, DRUG: Prednisone, DRUG: Vincristine Sulfate, DRUG: Methotrexate, PROCEDURE: Computed Tomography, PROCEDURE: X-Ray Imaging, DRUG: Vincristine, DRUG: Dasatinib, BIOLOGICAL: Blinatumomab, DRUG: Mercaptopurine, PROCEDURE: Biopsy Procedure, PROCEDURE: Echocardiography Test, PROCEDURE: Bone Marrow Aspiration and Biopsy, PROCEDURE: Lumbar Puncture, DRUG: Methotrexate Sodium
Lead Sponsor: Molecular Templates, Inc.
Intervention / Treatment: DRUG: MT-3724 Phase 1, DRUG: MT-3724 Phase 2
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Pegfilgrastim, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, DRUG: Dacarbazine, DRUG: Brentuximab Vedotin, PROCEDURE: Computed Tomography, BIOLOGICAL: Filgrastim, DRUG: Vinblastine Sulfate, DRUG: Doxorubicin Hydrochloride